- Home
- ANTA vs ALDX Comparison
ANTA vs ALDX Comparison
Compare ANTA & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | ALDX |
|---|---|---|
| Founded | 2022 | 2004 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 89.3M |
| IPO Year | 2024 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANTA | ALDX |
|---|---|---|
| Price | $3.45 | $1.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.17 | $5.50 |
| AVG Volume (30 Days) | 5.4K | ★ 660.9K |
| Earning Date | 06-16-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.95 | N/A |
| Revenue Next Year | $30.46 | N/A |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.00 | $1.07 |
| 52 Week High | $13.82 | $5.93 |
Technical Indicators
Market Signals| Indicator | ANTA | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 46.93 |
| Support Level | $3.00 | $1.47 |
| Resistance Level | $4.19 | $1.60 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 8.64 | 48.28 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.